AB
RARE icon

Amalgamated Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Amalgamated Bank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,551
Closed -$174K – 2541
2025
Q4 		$174K Buy
7,551
+325
+4% +$10.7K ﹤0.01% 1600
2025
Q3 		$217K Buy
7,226
+469
+7% +$14.1K ﹤0.01% 1553
2025
Q2 		$246K Buy
6,757
+598
+10% +$21.6K ﹤0.01% 1499
2025
Q1 		$223K Buy
6,159
+187
+3% +$7.78K ﹤0.01% 1506
2024
Q4 		$251K Buy
5,972
+76
+1% +$3.77K ﹤0.01% 1520
2024
Q3 		$328K Hold
5,896
– – ﹤0.01% 1448
2024
Q2 		$242K Buy
5,896
+696
+13% +$29.7K ﹤0.01% 1529
2024
Q1 		$243K Sell
5,200
-10,516
-67% -$496K ﹤0.01% 1543
2023
Q4 		$752K Buy
15,716
+1,427
+10% +$55.3K 0.01% 1270
2023
Q3 		$509K Sell
14,289
-398
-3% -$15.8K ﹤0.01% 1399
2023
Q2 		$678K Buy
14,687
+1,350
+10% +$62.6K 0.01% 1289
2023
Q1 		$535K Sell
13,337
-1,336
-9% -$57.3K ﹤0.01% 1391
2022
Q4 		$680K Buy
14,673
+251
+2% +$9.87K 0.01% 1317
2022
Q3 		$597K Buy
14,422
+134
+0.9% +$6.89K 0.01% 1348
2022
Q2 		$852K Buy
14,288
+117
+0.8% +$7.2K 0.01% 1206
2022
Q1 		$1.03M Buy
14,171
+968
+7% +$67.3K 0.01% 1186
2021
Q4 		$1.11M Buy
13,203
+1,524
+13% +$124K 0.01% 1177
2021
Q3 		$1.05M Sell
11,679
-688
-6% -$62.2K 0.01% 1219
2021
Q2 		$1.18M Buy
12,367
+3,318
+37% +$346K 0.01% 1211
2021
Q1 		$1.03M Sell
9,049
-724
-7% -$98.6K 0.04% 542
2020
Q4 		$1.35M Buy
9,773
+829
+9% +$98.3K 0.05% 382
2020
Q3 		$735K Sell
8,944
-128
-1% -$10.6K 0.03% 626
2020
Q2 		$710K Sell
9,072
-909
-9% -$60.2K 0.03% 612
2020
Q1 		$443K Sell
9,981
-660
-6% -$34.3K 0.01% 964
2019
Q4 		$454K Buy
10,641
+970
+10% +$40K 0.01% 1171
2019
Q3 		$414K Sell
9,671
-119
-1% -$6.46K 0.01% 1141
2019
Q2 		$622K Buy
9,790
+1,761
+22% +$112K 0.01% 964
2019
Q1 		$557K Buy
8,029
+1,142
+17% +$65.2K 0.01% 952
2018
Q4 		$299K Buy
6,887
+4,142
+151% +$226K 0.01% 1176
2018
Q3 		$210K Sell
2,745
-4,431
-62% -$360K 0.01% 1305
2018
Q2 		$552K Buy
7,176
+1,236
+21% +$79.8K 0.01% 974
2018
Q1 		$303K Buy
5,940
+553
+10% +$27.8K 0.01% 1205
2017
Q4 		$250K Buy
5,387
+351
+7% +$17.2K 0.01% 1362
2017
Q3 		$268K Buy
5,036
+56
+1% +$3.32K 0.01% 1290
2017
Q2 		$309K Buy
4,980
+352
+8% +$21.2K 0.01% 1183
2017
Q1 		$314K Buy
4,628
+202
+5% +$15.4K 0.02% 1102
2016
Q4 		$311K Buy
4,426
+616
+16% +$43.7K 0.01% 1114
2016
Q3 		$270K Buy
3,810
+5
+0.1% +$319 0.02% 1074
2016
Q2 		$260K Sell
3,805
-242
-6% -$15.7K 0.02% 1102
2016
Q1 		$256K Buy
4,047
+354
+10% +$23.2K 0.02% 979
2015
Q4 		$414K Sell
3,693
-334
-8% -$33.4K 0.05% 552
2015
Q3 		$388K Buy
4,027
+313
+8% +$35.8K 0.04% 690
2015
Q2 		$380K Buy
+3,714
New +$288K 0.04% 774

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Amalgamated Bank's RARE Position: Q1 2026 in Review

Amalgamated Bank sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 7,551 shares — an estimated $174K sold.

Amalgamated Bank first reported a position in RARE in Q2 2015 and held it in 43 quarters. The position peaked at $1.35M in Q4 2020. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Amalgamated Bank reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 7,551 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $174K.
  • Amalgamated Bank first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 43 quarters.
  • Amalgamated Bank's Ultragenyx Pharmaceutical position peaked at $1.35M in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.